Meridian Street Capital

VC New York, United States · Founded 2016

Meridian Street Capital is an early-stage venture capital firm investing exclusively at the intersection of technology and healthcare. They partner with founders at the earliest stages to build category-defining companies that improve patient health, access, costs, and experience.

About Meridian Street Capital

Meridian Street Capital is an Indianapolis-area investment firm whose name draws on a defining street in the city, signaling a Midwest-rooted, often Indiana-centric posture. The public footprint is consistent with a small growth or lower-middle-market private capital vehicle rather than a programmatic venture fund, with limited disclosure on thesis, stage, and check size. Healthcare exposure, where present, is plausibly oriented around the Indiana life-sciences cluster anchored by Eli Lilly, the Indiana University Health system, and Indiana’s strong medical-device and orthopedics manufacturing base, which could pull the firm into healthcare services, healthtech, or specialty manufacturing. AI focus is unstated and likely subordinate to deal type. Without explicit data, founders should anchor expectations toward later-stage minority growth investments or small control deals in profitable businesses rather than venture-style early-stage backing. This is the wrong door for pre-revenue founders, AI infrastructure plays, or any team that needs a thesis-aligned coastal venture lead. It is a plausible fit for revenue-positive Indiana or Midwest healthcare services and healthtech operators looking for patient regional capital and an investor with local network depth. Entry path is direct contact through the website and warm introductions through Indianapolis advisors, bankers, and operators. Founders should be ready with clean financials and a regional commercial story; growth-equity diligence and venture diligence look different, and the firm will run the former.

Founder reviews

No founder reviews yet. Raised from this fund? Share your experience with other founders.

Healthcare AI tools backed by Meridian Street Capital

Tools made by companies in Meridian Street Capital's portfolio that we cover in the directory.

Fibresolve (with PCCP)
Imvaria
Clinical Decision Support & Reference
IMVARIA is a health tech company pioneering AI-driven solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease.
ScreenDx
Imvaria
Clinical Decision Support & Reference
ScreenDx is a first-of-its-kind, FDA-cleared AI technology from Imvaria that automatically assesses CT scans for interstitial lung findings compatible with ILD, enhancing early detection and referral pathways.
Fibresolve
Imvaria
Clinical Decision Support & Reference
Fibresolve is the first FDA-authorized AI diagnostic service in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD), using non-invasive analysis to help drive diagnosis.
1up Platform
1upHealth
Developer Tools & APIs
1upHealth offers a FHIR-first data platform for health plans to acquire, manage, and use healthcare data, simplifying health data exchange and ensuring regulatory compliance.

Portfolio companies in our directory

Other portfolio companies

Companies in Meridian Street Capital's portfolio not currently in our directory.

Team

Scott Law
Partner
LinkedIn
George Ribaroff, MD
Partner
LinkedIn
Brianna Yarnoff
Investor
LinkedIn
Robel Mulugeta
Investor
LinkedIn
Jimmy Comfort
Venture Partner
LinkedIn

Pitch / review this investor

Have you raised from Meridian Street Capital? Founders only — share your honest experience (anonymous OK, moderated before publishing).

Share your experience
Last updated 2026-05-06. Sourced from this fund's published materials.
AI Tool Finder
AI-powered search. Results may not be comprehensive.